Protalix BioTherapeutics, Inc.

PLXAMEXHealthcare● Active

$1.96

$-0.03(-1.51%)

Market Cap$157920418

P/E Ratio—

52W High$3.19

52W Low$1.32

Avg Volume867K

Open$1.97

Beta0.01

Net Income Financials Revenue

Protalix BioTherapeutics, Inc. (PLX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

PLX · net income · updated Jun 9, 2026

Core profitability metrics

PLX · net income · margin · TTM · CAGR

Net income was −$6.6M for FY2025 (fiscal year ending 2025-12-31), down 325.2% year-over-year. Net profit margin was -12.5%. Based on available data, Protalix BioTherapeutics, Inc. has been profitable since at least 2015.

FY2025 Net Income−$6.6M▼ -325.2% YoY

Trailing 12M (TTM)$15.3Mtrailing 4 quarters sum

Net Profit Margin-12.5%−$6.6M ÷ $52.7M

YoY Change-325.2%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2015

▸ FMP /income-statement · Annual · PLX net income history · PLX profit margin

Annual net income data

PLX · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$6.6M▼ 325.2%-12.5%$52.7M

FY2024$2.9M▼ 64.7%5.5%$53.4M

FY2023$8.3M▲ +155.7%12.7%$65.5M

FY2022Loss−$14.9M▲ +45.9%-31.3%$47.6M

FY2021Loss−$27.6M▼ 322.8%-71.9%$38.4M

Net income vs peers (Healthcare)

PLX vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Protalix BioTherapeutics, Inc.YOU

PLX

−$6.6M-325.2%-12.5%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Protalix BioTherapeutics, Inc. (PLX) reported net income of −$6.6M for FY2025 (fiscal year ending 2025-12-31), down 325.2% year-over-year. The net profit margin was -12.5% — meaning the company kept $-0.13 of every dollar of revenue as profit.

Based on available data, Protalix BioTherapeutics, Inc. has been profitable since at least 2015. Net income reached a peak of $58.0M in FY2015. Data available for 15 fiscal years.

Protalix BioTherapeutics, Inc.'s net profit margin was -12.5% for FY2025, based on the latest annual results.

Investors sometimes search for "Protalix BioTherapeutics, Inc. net worth" — the company's market capitalization is a separate figure from PLX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

PLX net income · 5 questions

Protalix BioTherapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $6.6M for FY2025.

is PLX profitabledoes PLX make a profitPLX profitabilityPLX profitable company

▸ Source: FMP /income-statement · GAAP · Protalix BioTherapeutics, Inc. · Protalix BioTherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026